Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL)

  • Anticancer Res. 2020 Aug;40(8):4471-4479. doi: 10.21873/anticanres.14452.
Riri Yokota  1 ,  Shun Hashimoto  2 ,  Ikuko Watanabe  2 ,  Satoshi Kishimoto  2 ,  Masaaki Toyama  1 ,  Mika Okamoto  1 ,  Makoto Yoshimitsu  3 ,  Kenji Ishitsuka  3 ,  Yuji Ito  2 ,  Masanori Baba  4
Affiliations
  • 1. Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan.
  • 2. Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
  • 3. Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • 4. Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan [email protected].
PMID: 32727777 DOI: 10.21873/anticanres.14452
Abstract

Background/aim: Adult T-cell leukemia (ATL) is a hematological malignancy caused by Infection with human T-cell leukemia virus type 1 (HTLV-1). Chemotherapy, antibody therapy, and bone marrow transplantation are used to treat this disease, however, median survival time has not been significantly improved. Our aim was to develop and evaluate a novel antibody-drug conjugate (ADC) with regards to cell cytotoxicity and target specificity.

Materials and methods: In this study, we have constructed a novel ADC, which is composed of an anti-CD70 single chain Fv-Fc antibody conjugated with the Anticancer agent emtansine using a novel antibody modification method. Cell cytotoxicity and target specificity were assessed using a cell proliferation assay.

Results: The anti-CD70 ADC selectively killed HTLV-1-infected cells and ATL cells without affecting Other cells.

Conclusion: The anti-CD70 ADC offers some chemotherapeutic potential for the treatment of ATL.

Keywords
ATL; HTLV-1; antibody drug conjugate; cancer chemotherapy; immunotherapy.
Products